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Vascular and upper gastrointestinal eﬀ ects of non-steroidal 
anti-inﬂ ammatory drugs: meta-analyses of individual 
participant data from randomised trials
Coxib and traditional NSAID Trialists’ (CNT) Collaboration*
Summary
Background The vascular and gastrointestinal eﬀ ects of non-steroidal anti-inﬂ ammatory drugs (NSAIDs), including 
selective COX-2 inhibitors (coxibs) and traditional non-steroidal anti-inﬂ ammatory drugs (tNSAIDs), are not well 
characterised, particularly in patients at increased risk of vascular disease. We aimed to provide such information 
through meta-analyses of randomised trials.
Methods We undertook meta-analyses of 280 trials of NSAIDs versus placebo (124 513 participants, 68 342 person-
years) and 474 trials of one NSAID versus another NSAID (229 296 participants, 165 456 person-years). The main 
outcomes were major vascular events (non-fatal myocardial in farction, non-fatal stroke, or vascular death); major 
coronary events (non-fatal myocardial infarction or coronary death); stroke; mortality; heart failure; and upper 
gastrointestinal complications (perforation, ob struction, or bleed).
Findings Major vascular events were increased by about a third by a coxib (rate ratio [RR] 1·37, 95% CI 1·14–1·66; 
p=0·0009) or diclofenac (1·41, 1·12–1·78; p=0·0036), chieﬂ y due to an increase in major coronary events (coxibs 1·76, 
1·31–2·37; p=0·0001; diclofenac 1·70, 1·19–2·41; p=0·0032). Ibuprofen also signiﬁ cantly increased major coronary 
events (2·22, 1·10–4·48; p=0·0253), but not major vascular events (1·44, 0·89–2·33). Compared with placebo, of 
1000 patients allocated to a coxib or diclofenac for a year, three more had major vascular events, one of which was 
fatal. Naproxen did not signiﬁ cantly increase major vascular events (0·93, 0·69–1·27). Vascular death was increased 
signiﬁ cantly by coxibs (1·58, 99% CI 1·00–2·49; p=0·0103) and diclofenac (1·65, 0·95–2·85, p=0·0187), non-
signiﬁ cantly by ibuprofen (1·90, 0·56–6·41; p=0·17), but not by naproxen (1·08, 0·48–2·47, p=0·80). The proportional 
eﬀ ects on major vascular events were independent of baseline characteristics, including vascular risk. Heart failure 
risk was roughly doubled by all NSAIDs. All NSAID regimens increased upper gastrointestinal complications (coxibs 
1·81, 1·17–2·81, p=0·0070; diclofenac 1·89, 1·16–3·09, p=0·0106; ibuprofen 3·97, 2·22–7·10, p<0·0001; and 
naproxen 4·22, 2·71–6·56, p<0·0001).
Interpretation The vascular risks of high-dose diclofenac, and possibly ibuprofen, are comparable to coxibs, whereas 
high-dose naproxen is associated with less vascular risk than other NSAIDs. Although NSAIDs increase vascular and 
gastrointestinal risks, the size of these risks can be predicted, which could help guide clinical decision making.
Funding UK Medical Research Council and British Heart Foundation.
Introduction
Non-steroidal anti-inﬂ ammatory drugs (NSAIDs) are 
among the most widely used drugs in the world. They are 
chieﬂ y used to treat pain, but their long-term use is 
limited by serious gastrointestinal side-eﬀ ects. NSAIDs 
inhibit the two recognised forms of prostaglandin G/H 
synthase (also referred to as cyclo-oxygenase [COX]), 
namely COX-1 and COX-2.1 Since the analgesic and anti-
inﬂ ammatory eﬀ ects of NSAIDs are mediated by 
inhibition of COX-2, and their gastrointestinal side eﬀ ects 
mostly by inhibition of COX-1, NSAIDs which selectively 
inhibit COX-2 might reduce the risk of gastrointestinal 
toxicity compared with other NSAIDs. Several such 
COX-2 selective drugs (collectively known as coxibs) were 
developed in the 1990s, and early trials comparing coxibs 
versus traditional NSAIDs (tNSAIDS) seemed to conﬁ rm 
that coxibs at doses with similar analgesic eﬃ  cacy had 
less gastrointestinal toxicity.2,3 Unfortunately, however, 
subsequent placebo-controlled trials also showed 
unequivocally that coxibs were associated with an 
increased risk of atherothrombotic vascular events.4,5
Soon after these placebo-controlled trials were reported, 
a meta-analysis of randomised trials comparing a coxib 
versus placebo or a coxib versus tNSAID indicated that 
some tNSAIDs might also have adverse eﬀ ects on 
atherothrombotic events, but that these hazards might 
depend on the degree and duration of suppression of 
platelet COX-1.6 In these analyses, high-dose naproxen 
(generally 500 mg twice a day), which is alone among 
NSAID regimens in being able to induce near-
complete suppression of platelet thromboxane bio-
synthesis through out the 12-h dosing interval in some 
individuals,7 did not seem to increase the risk of 
atherothrombosis, but other high-dose tNSAID regimens 
with only transient eﬀ ects on platelet COX-1 were 
associated with a small, but deﬁ nite, vascular hazard.6 
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Similar ﬁ ndings have emerged in non-randomised 
observational studies of NSAIDs.8,9 The US Food and 
Drug Administration requires that the summaries of 
product characteristics of all NSAIDs carry a boxed 
warning about the risks of cardiovascular disease,10 
whereas the European Medicines Agency’s Committee 
for Medicinal Products for Human Use (CHMP) decided 
that coxibs (but not tNSAIDs11) should be contraindicated 
in patients with coronary heart disease or stroke, and 
used with caution in patients with risk factors for coronary 
heart disease.12 Because randomised trials avoid selection 
bias, they could provide more reliable estimates of the 
size, timing, and severity of any moderate cardiovascular 
hazards of NSAID regimens than observational studies 
(which are better suited to detecting large eﬀ ects). 
Accordingly, we initiated a collaborative meta-analysis of 
individual partici pant data (or, if not available, tabular 
data) from randomised trials of NSAIDs (the Coxib and 
traditional NSAID Trialists’ [CNT] Collaboration). The 
main objective was to characterise and quantify the 
cardiovascular and gastrointestinal risks of particular 
NSAID regimens among diﬀ erent types of patients, 
particularly those at increased risk of vascular disease.
Methods
Identiﬁ cation of trials and eligibility assessment
Searches of Medline and EMBASE were done using the 
Cochrane strategy13 (see appendix p 27 for details of search 
terms), with searches up to January, 2009, supplemented 
by subsequent periodic scrutiny of clinical trial registers 
(including www.clinicaltrials.gov and www.clinicaltrial-
results.org), review of reference lists of relevant papers, 
and enquiry among collaborators and pharmaceutical 
companies. For the present analyses, trials with results 
available prior to January, 2011, were eligible if they were 
properly randomised (ie, they used a randomisation 
method with robust allocation concealment), of at least 
4 weeks duration, and: involved a comparison of an 
NSAID versus placebo (or open control) or one NSAID 
regimen versus another NSAID regimen; and no other 
systematic diﬀ erences in drug treatment between treat-
ment arms were planned. All trials were reviewed for 
eligibility by two authors and information on key trial 
characteristics, including information pertaining to the 
risk of bias (method of randomisation, treatment masking, 
and publication status) were extracted and recorded. The 
secretariat sought individual participant data (or, where 
not available, aggregate data) from all eligible trials. 
Aggregate data in a standard format were either provided 
by trialists or, more commonly, data ﬁ elds were extracted 
from publications and checked by at least two authors. 
Four companies agreed to provide individual partici-
pant data from published and unpublished trials, 
including those involving celecoxib (Pﬁ zer), rofecoxib or 
etoricoxib (Merck), lumiracoxib (Novartis), and GW403681 
(GlaxoSmithKline). Individual participant data from trials 
of valdecoxib (Pﬁ zer) were requested but not provided, 
although aggregate data from these trials were included in 
our analyses. The US National Cancer Institute and the 
European Organisation for Research and Treatment of 
Cancer also provided individual participant data from any 
trials of NSAIDs they had sponsored.
Prespeciﬁ ed analyses
Intention-to-treat analyses of ﬁ rst events during the 
scheduled treatment periods were planned. Wherever 
available, adjudicated outcomes were used, but in a few 
trials only un-adjudicated outcomes based on standard 
Medical Dictionary of Regulatory Authorities (MedDRA) 
codes were available. The primary vascular outcome was 
major vascular events, deﬁ ned as non-fatal myocardial 
infarction, non-fatal stroke, or death from a vascular 
cause; subsidiary vascular outcomes included major 
coronary events (non-fatal myocardial infarction or 
death from coronary disease); stroke (subdivided into 
haemorrhagic, ischaemic, or unknown types), and 
hospitalisation for heart failure. Deaths were subdivided 
into vascular, non-vascular, and unknown causes. The 
primary gastro intestinal out come was upper gastro-
intestinal com pli cations, deﬁ ned as an upper gastro-
intestinal perfor ation, obstruction, or bleed. For subgroup 
analyses of the eﬀ ects of NSAIDs or for deﬁ ning ulcer risk 
categories, we used symptomatic upper gastro intestinal 
events, deﬁ ned as a symptomatic ulcer or upper gastro-
intestinal compli cation, to supplement statis tical power.
Statistical analysis
Meta-analyses of each comparison were done using 
standard logrank methods where individual patient data 
were available, or standard methods for 2 × 2 contingency 
tables otherwise.14,15 For each trial, the observed minus 
expected statistic (o – e) and its variance (v) were calcu-
lated. These (o – e) values, one from each trial, were 
summed to produce a grand total (G), with variance (V) 
equal to the sum of their separate variances. The one-step 
estimate of the log of the event rate ratio is G/V. The χ²n–1 
statistic for heterogeneity between the eﬀ ects in n 
diﬀ erent trials is S – (G² / V), where S is the sum over all 
the trials of [o – e]² / v. To help allow for multiple 
subdivisions of the data, only summary rate ratios 
(indicated by open diamonds in ﬁ gures) have 95% CI; all 
other rate ratios have 99% CIs. Rate ratios in diﬀ erent 
subgroups were compared by standard χ² tests for 
heterogeneity or, where the subgroups could be arranged 
in some meaningful order (eg, by dose), χ² tests for trend.
Rate ratios for the comparison tNSAID versus placebo 
were obtained by combining estimates obtained directly 
(from the small number of trials including such a 
comparison) with estimates obtained indirectly (from a 
comparison of trials of coxib vs tNSAID with trials of 
coxib vs placebo). For the calculation of indirect 
estimates of rate ratios for a tNSAID versus placebo, we 
used the following method.16 Let A be the set of trials 
involving a direct randomised comparison of a coxib 
For details of our study 
methods see http://www.ctsu.
ox.ac.uk/research/meta-trials/cnt
See Online for appendix
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versus placebo (but not also including the tNSAID of 
interest as a third group) and B the set of trials involving 
a direct randomised comparison of a coxib versus the 
tNSAID of interest (but not also including placebo as a 
third group). From A, we calculated the average log 
event rate ratio GA /VA for coxib versus placebo and, 
from B, the average log event rate ratio GB/VB for coxib 
versus tNSAID. These two results are independent of 
one another because A and B are non-overlapping sets 
of trials, so (subject to certain regularity assumptions) 
the log event rate ratio for tNSAID vs placebo can then 
be estimated indirectly by GA/VA – GB/VB (with variance 
Data available No data available* Total
IPD provided Tabular data only Total data available
Coxib vs placebo
Number of trials 113 71 184 6 190
Number of participants 73 635 (83%) 14 732 (17%) 88 367 (>99%) 238 (<1%) 88 605
Person-years† 46 407 (88%) 6 059 (12%) 52 466 (>99%) 164 (<1%) 52 630
Number of major vascular events (number of upper 
gastrointestinal complications)
436 (91) 46 (6) 482 (97) ·· ··
tNSAID vs placebo
Number of trials 47 111 158 30 188
Number of participants 18 018 (43%) 20 063 (48%) 38 081 (91%) 3 756 (9%) 41 837
Person-years† 8 253 (49%) 7 964 (47%) 16 217 (96%) 700 (4%) 16 917
Number of major vascular events (number of upper 
gastrointestinal complications)
45 (34) 25 (26) 70 (60) ·· ··
Coxib vs tNSAID
Diclofenac
Number of trials 27 6 33 2 35
Number of participants 58 891 (95%) 2681 (4%) 61 572 (>99%) 240 (<1%) 61 812
Person-years† 89 311 (99%) 1333 (1%) 90 644 (>99%) 21 (<1%) 90 665
Number of major vascular events (number of upper 
gastrointestinal complications)
762 (211) 11 (11) 773 (222) ·· ··
Ibuprofen
Number of trials 20 2 22 0 22
Number of participants 21 398 (96%) 827 (4%) 22 225 (100%) 0 22 225
Person-years† 11 508 (99%) 160 (1%) 11 668 (100%) 0 11 668
Number of major vascular events (number of upper 
gastrointestinal complications)
81 (82) 2 (0) 83 (82) ·· ··
Naproxen
Number of trials 34 14 48 1 49
Number of participants 42 222 (87%) 64 84 (13%) 48 706 (>99%) 66 (<1%) 48 772
Person-years† 30 040 (95%) 1591 (5%) 31 631 (>99%) 20 (<1%) 31 651
Number of major vascular events (number of upper 
gastrointestinal complications)
254 (213) 14 (12) 268 (225) ·· ··
Any tNSAID vs any other tNSAID
Number of trials 1 334 335 49 384
Number of participants 733 (1%) 67 774 (89%) 68 507 (90%) 7247 (10%) 75 754
Person-years† 134 (1%) 22 284 (94%) 22 418 (94%) 1323 (6%) 23 741
Number of major vascular events (number of upper 
gastrointestinal complications)
3 (0) 21 (105) 24 (105) ·· ··
Coxib vs other coxib
Number of trials 32 3 35 0 35
Number of participants 25 442 (98%) 489 (2%) 25 931 (100%) 0 25 931
Person-years† 9033 (99%) 60 (1%) 9093 (100%) 0 9093
Number of major vascular events (number of upper 
gastrointestinal complications)
59 (19) 1 (0) 60 (19) ·· ··
IPD=individual participant data. tNSAIDS=traditional non-steroidal anti-inﬂ ammatory drugs. *There were also seven trials involving a comparison of a coxib versus placebo, 
seven trials involving a comparison of a tNSAID versus placebo, one trial involving a comparison of a coxib versus ibuprofen, four trials involving a comparison of two 
diﬀ erent tNSAIDs, and one trial involving a comparison of two diﬀ erent coxibs for which the number of randomised patients was unknown. †Person-years for mortality.
Table: Availability of data for analyses
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1 / VA + 1 / VB). The overall (combined) estimate of the 
eﬀ ect of tNSAID versus placebo was calculated as the 
inverse variance weighted average of the direct and 
indirect estimates.
For each comparison, we assessed heterogeneity of 
treatment eﬀ ect in subgroups deﬁ ned by: demographic 
features (eg, age, sex); past medical history; physical 
measurements (eg, blood pressure); concomitant treat-
ments at baseline (eg, aspirin); and 5-year predicted 
risks of major vascular events (low [<5%], intermediate 
[5–10%], or high [>10%]) or of symptomatic upper gastro-
intestinal events (low [<5%], intermediate [5–10%], or 
high [>10%]). The predicted risks of each of the primary 
outcomes were modelled using Poisson regression, 
following a method described previously (appendix 
p28).17 Bonferroni corrections were applied for tests of 
heterogeneity to allow for multiple comparisons.
Role of the funding source
The sponsor of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to all 
the data in the study and had ﬁ nal responsibility for the 
decision to submit for publication.
Results
We found 24 278 titles and abstracts, from which we 
identiﬁ ed 639 randomised trials for analysis (appen-
dix p 4). The main NSAID regimens contributing infor-
mation on major vascular events, and their key 
pharmacological properties, are shown in the appen-
dix (p 1). Data from comparisons of coxib versus 
placebo were available in 184 trials (88 367 participants, 
52 466 person-years), and coxib versus tNSAID in 
113 trials (diclofenac in 33 trials, 61 572 partici-
pants, 90 644 person-years; ibuprofen in 22 trials, 
22 225 participants, 11 668 person-years; naproxen in 
48 trials, 48 706 participants, 31 631 person-years; and 
another tNSAID in 14 trials, 6192 participants, 
928 person-years; table). Almost all (roughly 99%) of 
primary outcomes occurred in trials involving a coxib or 
high-dose tNSAID (diclofenac 150 mg daily, ibuprofen 
2400 mg daily, or naproxen 1000 mg daily), and most 
such trials provided individual participant data (table).
Outcome
Major vascular events
Non-fatal MI
Coronary death
MI or CHD death
Non-fatal stroke
Stroke death
Any stroke
Other vascular death
Subtotal: major vascular events*
Heart failure
Cause-specific mortality
Vascular
Non-vascular
Unknown cause
Any cause
Upper gastrointestinal complications
Bleed
Perforation
Obstruction
Unknown
Subtotal: any complication
Rate ratio 
(direct evidence)
1·76 (1·31–2·37)
p=0·0001
2·22 (1·16–4·23)
p=0·0014
1·81 (1·17–2·81)
p=0·0070
1·58 (1·00–2·49)
1·00 (0·75–1·34)
1·50 (0·98–2·32)
1·22 (1·04–1·44)
p=0·0139
1·09 (0·78–1·52)
p=0·64
1·37 (1·14–1·66)
p=0·0009
2·28 (1·62–3·20)
p<0·0001
Events (% pa)
Allocated coxib Allocated placebo
 115 (0·54)
 27 (0·15)
 142 (0·63)
 80 (0·37)
 15 (0·08)
 94 (0·43)
 53 (0·26)
 307 (1·15)
 118 (0·66)
 95 (0·44)
 175 (1·32)
 95 (0·58)
 365 (1·66)
 53 (0·33)
 2 (0·03)
 2 (0·04)
 11 (0·52)
 68 (0·38)
 52 (0·29)
 12 (0·08)
 62 (0·33)
 59 (0·32)
 9 (0·05)
 67 (0·36)
 28 (0·16)
 175 (0·82)
 39 (0·26)
 49 (0·27)
 155 (1·35)
 61 (0·38)
 265 (1·42)
 20 (0·14)
 3 (0·06)
 3 (0·06)
 3 (0·40)
 29 (0·19)
Favours coxib Favours placebo
0·25 0·5 1 2 4
99% or 95% CI
Figure 1: Eﬀ ects of coxib therapy on major vascular events, heart failure, cause-speciﬁ c mortality, and upper gastrointestinal complications
Actual numbers for participants are presented, together with the corresponding mean yearly event rate (in parentheses). Participants can contribute only once to the total 
of major vascular events. Rate ratios (RRs) for all outcomes are indicated by squares and their 99% CIs by horizontal lines. Subtotals and their 95% CIs are represented by 
diamonds. Squares or diamonds to the left of the solid line indicate beneﬁ t. MI=myocardial infarction. CHD=coronary heart disease. Major vascular event=myocardial 
infarction, stroke, or vascular death. *Includes a further 25 vs 21 major vascular events in patients randomised into trials for which only tabular information was available.
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In trials providing individual participant data, the 
mean age at randomisation was 61 years, about two-
thirds were female, and 79% were white (appendix p 2). 
Few patients had a history of atherosclerosis (9%), of 
diabetes (9%), or of upper gastrointestinal peptic ulcer 
(7%). Mean body-mass index was 29 kg/m², blood 
pressure was 132/79 mm Hg, haemoglobin 137 g/L, 
creatinine 79 μmol/L, and total cholesterol 5·3 mmol/L. 
About a ﬁ fth of participants reported using aspirin at 
randomisation, 17% a proton-pump inhibitor, and 13% 
were current smokers. Overall, the indication for treat-
ment with an NSAID was rheumatoid arthritis or 
osteoarthritis in around four-ﬁ fths of participants, but in 
trials of a coxib versus placebo the indication was the 
prevention of colorectal adenomata or of Alzheimer’s 
disease in around a quarter of participants.
Compared with placebo (or, in a few cases, allocation to 
no NSAID treatment), the risk of major vascular events 
was increased by about a third in those allocated to a coxib 
(307 [1·15% per annum] coxib vs 175 [0·82% per annum] 
placebo; rate ratio [RR] 1·37, 95% CI 1·14–1·66, p=0·0009) 
or diclofenac (1·41, 1·12–1·78, p=0·0036), chieﬂ y due to an 
increase of about three-quarters in the risk of major 
coronary events (coxibs 1·76, 1·31–2·37, p=0·0001; diclo-
fenac 1·70, 1·19–2·41, p=0·0032; ﬁ gures 1, 2). Ibuprofen 
also signiﬁ cantly increased major coronary events (2·22, 
1·10–4·48, p=0·0253), but not major vascular events (1·44, 
0·89–2·33, p=0·14; ﬁ gure 3). By contrast with other 
tNSAIDs (heterogeneity p=0·04), high-dose naproxen was 
not associated with any signiﬁ cant excess risk of major 
vascular events (0·93, 0·69–1·27; ﬁ gure 4), and nor was 
there an increase in major coronary events (0·84, 
0·52–1·35). There was no evidence that any NSAID sig-
niﬁ cantly increased the risk of stroke (ﬁ gures 1–4).
The risk of hospitalisation due to heart failure 
was roughly doubled by all NSAID regimens studied 
(coxib 2·28, 95% CI 1·62–3·20, p<0·0001; diclofenac 
1·85, 1·17–2·94, p=0·0088; ibuprofen 2·49, 1·19–5·20, 
p=0·0155; naproxen 1·87, 1·10–3·16, p=0·0197; 
ﬁ gures 1–4).
The risk of vascular death was signiﬁ cantly increased 
by coxibs (1·58, 99% CI 1·00–2·49, p=0·0103) and 
diclofenac (1·65, 0·95–2·85, p=0·0187), non-signiﬁ cantly 
increased by ibuprofen (1·90, 0·56–6·41, p=0·17), but 
not increased by naproxen (1·08, 0·48–2·47, p=0·80; 
ﬁ gures 1–4). The risk of death from any cause was 
Outcome
Major vascular events
Non-fatal MI
Coronary death
MI or CHD death
Non-fatal stroke
Stroke death
Any stroke
Other vascular death
Subtotal: major vascular events
Heart failure
Cause-specific mortality
Vascular
Non-vascular
Unknown cause
Any cause
Upper gastrointestinal complications
Bleed
Perforation
Obstruction
Unknown
Subtotal: any complication
Adjusted rate ratio for 
diclofenac vs placebo
1·70 (1·19–2·41)
p=0·0032
2·20 (1·06–4·54)
p=0·0051
1·18 (0·79–1·78)
p=0·42
1·65 (0·95–2·85)
0·95 (0·57–1·58)
0·77 (0·22–2·73)
1·20 (0·94–1·54)
p=0·15
1·41 (1·12–1·78)
p=0·0036
1·85 (1·17–2·94)
p=0·0088
1·89 (1·16–3·09)
p=0·0106
Rate ratio (95% CI)
Coxib vs placebo Coxib vs diclofenac
1·71 (1·23–2·37)
1·72 (0·85–3·49)
1·76 (1·31–2·37)
1·04 (0·73–1·49)
1·46 (0·59–3·61)
1·09 (0·78–1·52)
1·55 (0·96–2·49)
1·37 (1·14–1·66)
2·28 (1·62–3·20)
1·58 (1·11–2·24)
1·00 (0·80–1·25)
1·50 (1·08–2·10)
1·22 (1·04–1·44)
2·22 (1·35–3·65)
0·51 (0·06–4·68)
0·49 (0·05–4·78)
1·50 (0·35–6·35)
1·81 (1·17–2·81)
1·09 (0·87–1·36)
0·71 (0·38–1·32)
1·04 (0·84–1·28)
0·86 (0·65–1·15)
1·47 (0·78–2·80)
0·92 (0·71–1·20)
0·93 (0·68–1·27)
0·97 (0·84–1·12)
1·23 (0·87–1·73)
0·96 (0·74–1·23)
1·05 (0·75–1·46)
1·96 (0·71–5·42)
1·02 (0·84–1·24)
1·01 (0·75–1·36)
0·42 (0·13–1·37)
1·18 (0·20–7·00)
0·76 (0·22–2·68)
0·94 (0·72–1·24)
Favours diclofenac Favours placebo
0·25 0·5 1 2 4
99% or 95% CI
Figure 2: Eﬀ ects of diclofenac on major vascular events, heart failure, cause-speciﬁ c mortality, and upper gastrointestinal complications (indirect comparisons)
Rate ratios (RRs) are for comparisons of a tNSAID versus placebo, calculated indirectly from ratio of RRs for a coxib versus placebo and RRs for a coxib versus tNSAID, 
each of which is shown in the vertical columns (see statistical methods). MI=myocardial infarction. CHD=coronary heart disease. 
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signiﬁ cantly increased by around a quarter by allocation 
to a coxib (1·22, 1·04–1·44, p=0·0139), but despite a clear 
excess of vascular deaths the corresponding excess was 
not signiﬁ cant for diclofenac (1·20, 0·94–1·54, p=0·15), 
and nor were there signiﬁ cant excesses of death from 
any cause for ibuprofen (1·61, 0·90–2·88, p=0·11) or 
naproxen (1·03, 0·71–1·49, p=0·88).
Compared with placebo, there was an increased risk 
of upper gastrointestinal complications (most of which 
were bleeds) in association with allocation to a coxib 
(68 [0·38% per annum] coxib vs 29 [0·19% per annum] 
placebo; 1·81, 1·17–2·81, p=0·0070), diclofenac (1·89, 
1·16–3·09, p=0·0106), ibuprofen (3·97, 2·22–7·10, 
p<0·0001), and naproxen (4·22, 2·71–6·56, p<0·0001; 
appendix p 3 and ﬁ gures 1–4). Only 2% of upper gastro-
intestinal compli cations were recorded as being fatal.
There was very little power to assess variation in 
treatment eﬀ ects on major vascular events or on sympto-
matic upper gastrointestinal events in patient subgroups; 
however, for each of the main categories of NSAIDs 
studied, after allow ance for multiple com parisons, the 
proportional eﬀ ects on each speciﬁ c outcome seemed 
similar in diﬀ erent types of patients, including those at 
low, intermediate, and high risk of major vascular events 
and those at diﬀ ering risk of symptomatic upper gastro-
intestinal events (Bonferroni-adjusted hetero geneity 
p values all >0·1; appendix pp 5–14).
There was only limited evidence for an increased risk 
of major vascular events during the ﬁ rst 6 months for 
coxibs (p=0·06) and diclofenac (p=0·0329), and no 
evidence that any proportional excess increased with 
greater exposure to treatment (p values all non-
signiﬁ cant; appendix p 15). For symptomatic upper 
gastro intestinal ulcers, however, a more deﬁ nite pattern 
of excess within the ﬁ rst 6 months was seen for coxibs 
(2·55, 99% CI 1·49–4·35), diclofenac (3·93, 2·16–7·13), 
ibuprofen (5·73, 3·24–10·14), and naproxen (6·31, 
3·81–10·44; appendix p 16).
Overall, celecoxib and rofecoxib signiﬁ cantly increased 
the risks of major vascular events (celecoxib 1·36, 95% CI 
1·00–1·84; rofecoxib 1·38, 1·07–1·80; appendix pp 17, 18). 
There was a smaller proportional excess risk of major 
vascular events with lower celecoxib doses in placebo-
controlled trials (p for trend=0·0117; appendix p 18). 
Etoricoxib had not been extensively studied in placebo-
controlled trials (appendix p 17), but the eﬀ ects of 
etoricoxib, rofecoxib, and celecoxib seemed similar 
(heterogeneity p=0·21; appendix p 19) in trials of a coxib 
Figure 3: Eﬀ ects of ibuprofen on major vascular events, heart failure, cause-speciﬁ c mortality, and upper gastrointestinal complications (indirect comparisons)
MI=myocardial infarction. CHD=coronary heart disease. NE=not estimated.
Outcome
Major vascular events
Non-fatal MI
Coronary death
MI or CHD death
Non-fatal stroke
Stroke death
Any stroke
Other vascular death
Subtotal: major vascular events
Heart failure
Cause-specific mortality
Vascular
Non-vascular
Unknown cause
Any cause
Upper gastrointestinal complications
Bleed
Perforation
Obstruction
Unknown
Subtotal: any complication
Adjusted rate ratio for 
ibuprofen vs placebo
2·22 (1·10–4·48)
p=0·0253
0·97 (0·42–2·24)
p=0·95
3·63 (1·09–12·12)
p=0·0059
3·97 (2·22–7·10)
p<0·0001
1·90 (0·56–6·41)
2·02 (0·10–40·19)
2·01 (0·67–6·07)
1·61 (0·90–2·88)
p=0·11
1·44 (0·89–2·33)
p=0·14
2·49 (1·19–5·20)
p=0·0155
Rate ratio (95% CI)
Coxib vs placebo Coxib vs ibuprofen
1·71 (1·23–2·37)
1·72 (0·85–3·49)
1·76 (1·31–2·37)
1·04 (0·73–1·49)
1·46 (0·59–3·61)
1·09 (0·78–1·52)
1·55 (0·96–2·49)
1·37 (1·14–1·66)
2·28 (1·62–3·20)
1·58 (1·11–2·24)
1·00 (0·80–1·25)
1·50 (1·08–2·10)
1·22 (1·04–1·44)
2·22 (1·35–3·65)
0·51 (0·06–4·68)
0·49 (0·05–4·78)
1·50 (0·35–6·35)
1·81 (1·17–2·81)
0·91 (0·43–1·94)
0·41 (0·06–2·95)
0·81 (0·41–1·61)
1·00 (0·43–2·33)
NE
1·00 (0·44–2·25)
1·11 (0·32–3·84)
0·92 (0·58–1·46)
0·83 (0·42–1·64)
0·83 (0·32–2·16)
0·49 (0·03–9·27)
0·79 (0·34–1·84)
0·78 (0·43–1·42)
0·55 (0·24–1·30)
NE
NE
0·32 (0·18–0·58)
0·40 (0·25–0·64)
Favours ibuprofen Favours placebo
0·25 0·5 1 2 4
99% or 95% CI
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versus diclofenac (where the same diclofenac regimen 
was used in each trial). Similarly, trials of lumiracoxib 
versus placebo provided little useful information, whereas 
trials of lumiracoxib versus ibuprofen or lumiracoxib 
versus naproxen (1000 mg in seven trials, 440 mg in one 
trial) were consistent with the vascular risks of lumiracoxib 
being similar to other coxibs (Bonferroni-adjusted hetero-
geneity p values all >0·1; appendix pp 20, 21).
In comparable analyses of symptomatic upper gastro-
intestinal events, there was also a lack of evidence of 
heterogeneity between coxibs in comparisons with 
placebo, diclofenac, ibuprofen, and naproxen (Bonferroni-
adjusted heterogeneity p values all >0·1; appendix 
pp 22–26), suggesting that each of the coxibs yielded 
similar ulcer risks. For several of them, however, there 
was evidence that higher doses yielded larger proportional 
excesses in ulcer risk (celecoxib: p for trend=0·0043; 
rofecoxib: p for trend=0·0350; appendix p 25; etoricoxib: 
heterogeneity p=0·0135; appendix p 24).
Discussion
Meta-analyses of ran domised trials and of observational 
studies have shown that coxibs and tNSAIDs are 
associated with an increased risk of cardiovascular 
disease and upper gastrointestinal complications,5,6,8,18–20 
but there has been uncertainty about the nature and 
magnitude of these risks, and the relative safety of 
diﬀ erent NSAID regimens, especially in those at 
increased risk of coronary heart disease.10–12
Our meta-analysis, which is unaﬀ ected by selection 
and other biases inherent in observational studies, 
showed clearly that the vascular risks of diclofenac, and 
possibly ibuprofen, are similar to coxibs, but that 
naproxen is not associated with an increased risk of 
major vascular events. However, it also showed that the 
excess risk of both vascular and gastrointestinal events 
can be predicted once the baseline risks of such hazards 
are known, which could help clinical decision-making.
Most of the information available for the estimation of 
vascular risks was derived from trials involving four coxibs 
(celecoxib, rofecoxib, etoricoxib, and lumiracoxib) and 
three high-dose tNSAID regimens (daily doses: diclofenac 
150 mg, ibuprofen 2400 mg, and naproxen 1000 mg [table 
and appendix]). Overall, coxibs increased the risk of major 
vascular events by around a third, as previously reported 
in meta-analyses of summary trial data,6 but these analyses 
show that the excess risk was mainly attributable to an 
increase of about three quarters in the risk of major 
Outcome
Major vascular events
Non-fatal MI
Coronary death
MI or CHD death
Non-fatal stroke
Stroke death
Any stroke
Other vascular death
Subtotal: major vascular events
Heart failure
Cause-specific mortality
Vascular
Non-vascular
Unknown cause
Any cause
Upper gastrointestinal complications
Bleed
Perforation
Obstruction
Unknown
Subtotal: any complication
Adjusted rate ratio for 
naproxen vs placebo
0·84 (0·52–1·35)
p=0·48
0·97 (0·59–1·60)
p=0·90
5·49 (2·74–10·99)
p<0·0001
1·08 (0·48–2·47)
0·74 (0·17–3·13)
1·51 (0·70–3·24)
1·03 (0·71–1·49)
p=0·88
0·93 (0·69–1·27)
p=0·66
1·87 (1·10–3·16)
p=0·0197
4·22 (2·71–6·56)
p<0·0001
Rate ratio (95% CI)
Coxib vs placebo Coxib vs naproxen
1·71 (1·23–2·37)
1·72 (0·85–3·49)
1·76 (1·31–2·37)
1·04 (0·73–1·49)
1·46 (0·59–3·61)
1·09 (0·78–1·52)
1·55 (0·96–2·49)
1·37 (1·14–1·66)
2·28 (1·62–3·20)
1·58 (1·11–2·24)
1·00 (0·80–1·25)
1·50 (1·08–2·10)
1·22 (1·04–1·44)
2·22 (1·35–3·65)
0·51 (0·06–4·68)
0·49 (0·05–4·78)
1·50 (0·35–6·35)
1·81 (1·17–2·81)
2·02 (1·35–3·02)
2·46 (0·71–8·50)
2·11 (1·44–3·09)
1·19 (0·76–1·86)
0·89 (0·21–3·81)
1·14 (0·74–1·73)
1·49 (0·74–3·00)
1·49 (1·16–1·92)
1·17 (0·76–1·79)
1·53 (0·89–2·62)
1·61 (0·54–4·77)
0·90 (0·52–1·57)
1·23 (0·86–1·75)
0·34 (0·23–0·49)
0·78 (0·17–3·61)
NE
0·39 (0·25–0·60)
0·37 (0·28–0·49)
Favours naproxen Favours placebo
0·25 0·5 1 2 4
99% or 95% CI
Figure 4: Eﬀ ects of naproxen on major vascular events, heart failure, cause-speciﬁ c mortality, and upper gastrointestinal complications (indirect comparisons)
MI=myocardial infarction. CHD=coronary heart disease.
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coronary events. These results are similar to those 
previously reported for coxibs, diclofenac, ibuprofen, and 
naproxen in ob servational studies8 but, by contrast with 
the present meta-analysis of randomised trials, the 
observational studies used a wide range of vascular 
outcomes and tNSAID doses, so precise comparisons 
between these diﬀ erent types of studies are not possible.
This meta-analysis showed clearly that high-dose 
diclofenac has similar vascular risks to the average coxib 
regimen studied. The absolute excess risks were small but 
serious: compared with placebo, allocation to a coxib or 
diclofenac caused around three additional major vascular 
events per 1000 participants per year, with one such event 
causing death. High-dose ibuprofen also signiﬁ cantly 
increased the risk of major coronary events, but there 
were many fewer relevant events in trials of coxib versus 
ibuprofen, so its safety (including the possible relevance 
of its interaction with aspirin21) requires further study. 
Naproxen 500 mg twice a day did not seem to increase the 
risk of major vascular events, consistent with experimental 
studies showing that this naproxen regimen is capable of 
producing COX-1 inhibition that is suﬃ  ciently prolonged 
and intense to result in platelet inhibition in some 
individuals, which could attenuate any adverse vascular 
eﬀ ects of COX-2 inhibition.7
There was no evidence of an increased risk of stroke for 
any of the NSAIDs studied, but few strokes were recorded 
and the absence of any stroke risk for drug regimens 
known to increase blood pressure is implausible. All 
NSAIDs doubled the risk of heart failure causing hospital 
admission (ie, not just ankle oedema), consistent with this 
being a COX-2 dependent hazard unrelated to variable 
platelet inhibition. As expected, NSAIDs increased the 
risk of upper gastrointestinal complications by around 
2–4 times and, as previously shown by individual trials,2,3 
coxibs yielded the lowest risk of such complications.
Our analyses do not allow deﬁ nite conclusions about 
whether particular NSAIDs increase vascular risk imme-
diately after starting treatment, but evidence for an early 
hazard of coxibs would have been enhanced if data had 
been included from two trials that indicated vascular 
hazard from intravenous parecoxib followed by oral 
valdecoxib during a 2-week period after coronary artery 
bypass surgery.22,23 There was, however, clear evidence 
that NSAIDs increase the early risk of upper gastro-
intestinal complications. Since the average trial duration 
was less than 1 year, our analyses do not provide reliable 
information about whether the risks of NSAIDs persist 
with prolonged treatment (and since events occurring 
more than a few weeks after patients discontinued 
treatment were not generally recorded, our analyses 
might underestimate those risks).
Overall, at the daily doses studied most frequently, the 
vascular risks of diﬀ erent coxib regimens seemed similar. 
Little information was available on whether the vascular 
hazards of coxibs were dose-dependent. Although there 
was a trend towards less risk with lower celecoxib doses, 
the vascular eﬀ ects of celecoxib 200 mg daily (the most 
widely used coxib regimen) were statistically uncertain. 
The tNSAID regimens studied were all high-dose, with 
little variation between trials, so comparable analyses of 
tNSAIDs were not possible. However, since vascular 
hazard is probably related to the degree of COX-2 
inhibition, which increases with dose,9 such dose-
dependency seems likely.24
The potential for bias has been minimised in this meta-
analysis by obtaining access to detailed individual data 
from most trials recording vascular and gastrointestinal 
outcomes (including some that were unpublished). Since 
most events occurred in a small number of recent trials 
Figure 5: Annual absolute eﬀ ects per 1000 of coxibs and tNSAIDs at diﬀ erent baseline risks of major vascular 
events and upper gastrointestinal complications
For each category of drug (coxib, diclofenac, ibuprofen, and naproxen), the predicted annual absolute risks of major 
vascular events (±1 SE) are shown (left) for patients with predicted risk of 2·0% or 0·5% per annum of a major 
vascular event. For comparison, predicted annual absolute risks of upper gastrointestinal complications (±1 SE) 
are shown for patients with predicted risks of 0·5% or 0·2% per annum (right). Absolute annual risks for 
placebo-allocated patients are assumed to be those of a hypothetical patient after all appropriate forms of 
prophylactic treatment (eg, antihypertensive therapy, statin therapy, proton-pump inhibitors) have been instituted.
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that used secure randomisation methods and treatment 
blinding, sensitivity analyses (available on request) 
indicated that our results were not materially inﬂ uenced 
by uncertainties about the quality of older trials. There 
was also no evidence that our results depended on 
whether participating trials had been published, although 
some unpublished trials of which we were unaware 
might have aﬀ ected particular ﬁ ndings. A novel element 
of our analyses was that treatment eﬀ ects were estimated 
by comparing the results of trials of a coxib versus placebo 
and trials of a coxib versus tNSAID. The conditions under 
which such indirect comparisons might be expected to 
yield valid results25 are satisﬁ ed, since the two sets of trials 
involved similar doses of coxibs and similar populations, 
and diﬀ erent studies used the same (high-dose) tNSAID 
regimens as comparators.
A key objective was to quantify the hazards of NSAIDs 
in patients with an increased risk of vascular disease. The 
results of a previous meta-analysis suggested that the 
proportional increase in vascular risk might be highest 
for celecoxib in those at greatest risk of coronary heart 
disease.26 In our meta-analysis, however, the proportional 
eﬀ ects of coxibs and tNSAIDs seemed similar irrespective 
of baseline characteristics, and in particular were similar 
at all levels of risk of major vascular events (<5%, 5–10%, 
>10% over 5 years), although there were limited 
data among patients with a history of atherosclerosis. 
Assum ing that proportional eﬀ ects are indeed similar in 
diﬀ erent patients, we undertook hypothetical calculations 
(appendix) of the annual excess risks of each of the main 
NSAIDs as compared with placebo (ﬁ gure 5). Excess risks 
were calculated for major vascular events in patients at 
high (2% per annum) or low (0·5%) risk of major vascular 
events (left panel), and for upper gastrointestinal com-
plications in patients at moderate (0·5% a year) or low 
(0·2% a year) risk of such complications (right panel). For 
each outcome, the fraction of fatal events is shown in 
darker shading. Among those at low risk of vascular 
disease (the majority of participants in these trials), the 
predicted absolute risks of major vascular events were 
small irrespective of the particular regimen chosen. For 
high-risk individuals (about 40% of whom were taking 
aspirin), for every 1000 patients allocated to a year of 
treatment with a coxib regimen or high-dose diclofenac 
regimen, about seven or eight more would have a major 
vascular event, of which two would be fatal. High-dose 
ibuprofen may be associated with a similar risk, but is 
also likely to yield a higher risk of upper gastrointestinal 
complications than either a coxib or diclofenac.
Our analyses suggest that naproxen might not be 
associated with an increased risk of major vascular 
events, but this result should be interpreted with caution. 
First, we do not know whether this would be true in 
patients treated with aspirin, in whom naproxen will not 
result in any additional inhibition of COX-1 and might 
actually interfere with the antiplatelet eﬀ ect of low-dose 
aspirin.27,28 Secondly, the eﬀ ects of lower naproxen doses, 
such as those typically used in over-the-counter prepar-
ations (eg, 220 mg twice a day), are uncertain since they 
would be less likely to mimic the aspirin-like eﬀ ect of 
500 mg twice a day.29 Thirdly, the apparent advantage of 
naproxen regimens might not be preserved after longer 
term use. Finally, naproxen substantially increases the 
risk of upper gastrointestinal complications (although 
such bleeds are less likely than vascular events to result 
in disability30 and such hazards could be mitigated with 
proton-pump inhibitors31).
This meta-analysis of individual participant data helps 
to characterise and quantify the vascular and gastro-
intestinal hazards of coxibs and tNSAIDs. It shows that 
high-dose diclofenac has vascular risks similar to coxibs, 
but also raises the possibility that high-dose ibuprofen 
has similar vascular eﬀ ects. High-dose naproxen seems 
to be associated with less vascular hazard, although 
whether this is true of the lower doses most commonly 
used in clinical practice is unclear. Although NSAIDs 
increase vascular and gastrointestinal risks to a varying 
extent, our analyses indicate that the eﬀ ects of diﬀ erent 
regimens in particular patients can be predicted, which 
could help in guiding decisions about the clinical 
management of inﬂ ammatory disorders.
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